首药控股：MAT2A抑制剂SY-9453获得药物临床试验批准通知书

Core Viewpoint - The company Shouyao Holdings (688197.SH) has received approval from the National Medical Products Administration for a clinical trial of SY-9453 capsules, aimed at treating locally advanced or metastatic solid tumors with homozygous deletion of methylthioadenosine phosphorylase (MTAP) [1] Group 1 - The clinical trial approval is specifically for the use of SY-9453 as a monotherapy [1] - The targeted condition for the trial involves patients with a specific genetic mutation, indicating a focused approach in oncology [1]